November 22, 2026:


World AMR Awareness Week runs through Nov. 24 with a new 10-year global plan on antimicrobial resistance (AMR) behind it, yet the latest country survey shows only 42 countries have funded their national plans. The gap matters to anyone who may need surgery, cancer treatment or childbirth care, because WHO officials warned in Geneva on Nov. 16 that resistance could cause 39 million deaths over the next 25 years and make routine procedures life-threatening.
The week opened Nov. 18 under the theme “One Health, one action: Prevent AMR now,” and WHO’s campaign page points to the updated Global Action Plan the World Health Assembly adopted in May. FAO, UNEP, WHO and the World Organisation for Animal Health (WOAH), the four agencies of the Quadripartite, each host campaign pages for the week. Fresh surveillance data from WHO Europe and the Pan American Health Organization (PAHO) landed Nov. 18, and both show resistance still rising in hospital bacteria, according to the European Centre for Disease Prevention and Control’s urgent action release and PAHO’s Nov. 18 release.
The count comes from the Tracking AMR Country Self-Assessment Survey (TrACSS), which 183 of 194 countries answered this year, according to Health Policy Watch. Pravasha Prakash, an AMR technical officer at WHO, told a Nov. 16 media forum that only 42 countries had a plan that was financed, implemented and monitored. Al Jazeera’s report called that fewer than one in five countries, while Health Policy Watch put it at 22%; the percentages differ by outlet, but the count of 42 is consistent.
The 2024 UN General Assembly declaration set a different bar: at least 60% of countries with funded national plans by 2030, backed by US$100 million in catalytic funding. Earlier data pointed the same way: only 10% of countries reported dedicated domestic funding for their plans in 2024, and 29% had costed and budgeted plans.
Donor money is also shrinking. Official development assistance from major donors fell 23.1% in real terms in 2025, the largest annual drop on record, across all sectors rather than health alone.
Member states adopted the updated plan, known as GAP-AMR, in May, the first overhaul since 2015. The 2015 approach leaned on new drugs; the new plan names infection prevention and control, water and sanitation, vaccination, biosecurity, husbandry practices and pollution prevention as primary tools, with drug development as a complement. It also writes environmental duties into a global AMR plan for the first time, covering pharmaceutical manufacturing discharges, healthcare wastewater and agricultural runoff. Antibiotic factory effluent is a documented hot spot: a study near a veterinary antibiotic plant in Shijiazhuang, China, found resistance genes downstream in river water and soil.
The plan’s numbers are mostly inherited. WHO’s campaign page lists targets to cut bacterial AMR deaths, reduce antimicrobial use (particularly in agrifood systems) and minimize environmental pollution, but gives no figures. The headline goal, a 10% cut in bacterial AMR-associated deaths by 2030, comes from the 2024 UN declaration and is measured against a 2019 baseline of 4.95 million deaths. The Director-General is to report to the Assembly in 2027, 2029 and 2031, and WOAH is asked to build a veterinary counterpart to WHO’s AWaRe system, which sorts antibiotics into Access, Watch and Reserve groups, according to Health Policy Watch.
Financing is where the plan is thinnest. WHO’s adoption notice says the plan reinforces sustainable financing but states no amounts or mechanisms, and China urged a dedicated One Health financing window during the debate. The agrifood side is also unquantified: WOAH’s 183 members adopted their version on May 21, and FAO and UNEP were still working through approvals as of July reporting. The 2024 declaration also omitted a 30% animal-antibiotic reduction target, a choice critics call a major weakness and meat-producing countries opposed.
That question nearly stalled the plan. It was postponed at the February Executive Board after Brazil, Colombia and Indonesia objected to wording that limited technology transfers to “voluntary and mutually agreed” terms. The compromise text promotes knowledge sharing and transfer of AMR-related technologies while respecting international and national rules.
Each side reads that differently. Access advocates say the reference to national and international rules leaves room for compulsory licensing in a crisis, and Knowledge Ecology International said it welcomed the removal of the earlier language. The UK said it will interpret the text as promoting voluntary, mutually agreed transfer, Germany said the same rules include voluntary transfer on mutually agreed terms, and the pharmaceutical trade group IFPMA broadly supports the plan while urging priority for voluntary terms, according to the same Health Policy Watch report.
A compulsory license lets a government authorize use of a patent without the owner’s consent in exchange for payment, and Article 31 of the WTO’s TRIPS agreement sets the conditions for doing so. The practical question is who may legally make antibiotics and diagnostic tests in regions that now import them.
Antibiotic susceptibility testing measures how well bacteria respond to specific drugs, which lets clinicians move from an educated guess to treatment based on the organism’s actual profile. Disc diffusion, the cheapest method, reads the clearing zone around an antibiotic-soaked disc on an agar plate, while broth dilution finds the lowest concentration that stops growth, known as the minimum inhibitory concentration, and is considered the gold standard. Culture-based results typically take 12 to 48 hours and sometimes up to five days. Rapid molecular tests, defined as feasible within an eight-hour working shift, can detect resistance genes such as mecA in MRSA but are costly, need trained staff and do not always match what the bacteria actually do. A 2024 Longitude Prize winner, Sysmex Astrego, reported a 45-minute point-of-care urinary tract infection test.
That lag shapes what a plan can achieve. Silvia Bertagnolio, head of AMR surveillance and laboratory strengthening at WHO, said that even in their best-equipped laboratory, more than one in four countries cannot test for resistance in the bacteria WHO monitors. In the TrACSS data, 131 countries (72%) can test for selected bacteria and 72 countries (39%) for selected fungi, against a 2030 target of 80% of countries testing all monitored pathogens. Without testing, clinicians must treat without knowing which antibiotic will work, WHO’s surveillance chief said.
WHO released two tools on Nov. 16 to close the gap: a 52-page essential package of diagnostic tests mapped to each tier of the health system, from primary care to tertiary hospitals, and a compilation of 73 laboratory procedures running from sample collection to susceptibility testing. The two numbers, funded plans and working labs, measure different things: a plan on file does not change a prescription in a hospital that cannot culture a sample.
PAHO’s Nov. 18 release said resistance to carbapenems, last-line antibiotics, in Klebsiella pneumoniae rose from about 15% in 2015 to 26% in 2024 across 15 reporting countries. E. coli resistance rose from 3% to 5% across 13 countries, and median carbapenem resistance in Acinetobacter baumannii reached 77% across seven countries. The Americas’ regional plan for 2027 to 2031 was approved in September, and the release does not mention its funding.
WHO Europe and the European Centre for Disease Prevention and Control reported the same day that bloodstream infections with carbapenem-resistant Klebsiella pneumoniae rose an estimated 72% between 2019 and 2025 against a target of a 5% cut, and that cephalosporin-resistant E. coli infections rose more than 16% against a target of a 10% drop. Of 51 countries analyzed, 16 still lack a standardized national approach, and few blood samples are taken for testing, leaving health systems “planning half-blind,” WHO said.
For US readers, the nearest benchmark is the CDC’s antimicrobial resistance threats report, published Oct. 27, which estimated about 9.7 million infections and 50,800 deaths from resistant pathogens in 2023. The 2019 report, built on 2013 data, estimated 2.8 million infections and 35,000 deaths, but the CDC advises against comparing the two directly because data sources and methods changed. Healthcare-associated infections accounted for more than 42,000 of the 2023 deaths and nearly $12 billion in costs, and Candidozyma auris cases reached 4,523, roughly tenfold the 2019 count.
The Infectious Diseases Society of America’s president, Wendy S. Armstrong, urged Congress to pass the PASTEUR Act to fund new antimicrobials and stewardship programs. The US is not among the member states that adopted the WHO plan: it completed its withdrawal from WHO on Jan. 22, and HHS said it will continue global health leadership through direct engagements with other countries.
The Fifth Global High-Level Ministerial Conference on AMR is scheduled for Dec. 6 to 8 in Abuja, Nigeria, the first on African soil, and is expected to adopt an Abuja Compact. A draft of the compact asks governments to include AMR spending in routine budgets and asks the World Bank and regional development banks to weigh AMR in grants and lending, according to Health Policy Watch. The meeting was originally planned for June before it was rescheduled.
Readers weighing what comes next can track three numbers: how many countries fund their plans (42 today), how many can test for resistance (72% for selected bacteria, 39% for selected fungi) and whether the technology-transfer language lets regions make their own antibiotics and tests. Abuja is the next meeting where governments can attach budgets and dates to a plan whose adoption notice states no financing amounts, and a rise in the count of 42 would be the clearest sign that awareness is turning into action.
No. A plan records intent, while detection depends on laboratories: 72% of countries can test selected bacteria and 39% selected fungi, and only 42 countries report plans that are financed, implemented and monitored. Without a lab that can run susceptibility tests, clinicians prescribe on a best guess.
It traces to the Global Research on Antimicrobial Resistance (GRAM) project’s 2024 forecast of 39 million deaths from 2025 to 2050, which UNEP describes as directly attributable to bacterial AMR. WHO officials restated it on Nov. 16 as deaths over the next 25 years.
The CDC’s latest report lists four urgent threats: Candidozyma auris (formerly Candida auris), carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
PAHO’s campaign advice is to use antibiotics only when prescribed by a doctor or veterinarian, follow treatment instructions, handle food safely and hygienically, and not dispose of medicines down the drain.